{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T19:12:31Z","timestamp":1777317151962,"version":"3.51.4"},"reference-count":80,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Emerg Med J"],"accepted":{"date-parts":[[2015,4,13]]},"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:p>Long-term oral anticoagulant (OAC) therapy is used for the treatment and prevention of thrombosis and thromboembolism. As OAC use is so widespread, emergency physicians are likely to encounter patients on anticoagulant therapy in the emergency department (ED) on a regular basis, either for the same reasons as the population in general or as a result of the increased bleeding risk that OAC use entails.<\/jats:p>\n                  <jats:p>The vitamin K antagonist warfarin has been the standard OAC for several decades, but recently, the newer agents dabigatran etexilate, rivaroxaban and apixaban (collectively, novel OACs, non-vitamin K OACs, or simply \u2018NOACs\u2019) have become available for long-term use. Protocols for assessing and managing warfarin-treated patients in the ED are well established and include international normalised ratio (INR) testing, which helps guide patient management. However, the INR does not give an accurate evaluation of coagulation status with NOACs, and alternative tests are therefore needed for use in emergency settings. This paper discusses what information the INR provides for a patient taking warfarin and which coagulation tests can guide the physician when treating patients on one of the NOACs, as well as other differences in emergency anticoagulation management.<\/jats:p>","DOI":"10.1136\/emermed-2015-204891","type":"journal-article","created":{"date-parts":[[2015,5,18]],"date-time":"2015-05-18T22:30:48Z","timestamp":1431988248000},"page":"423-430","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":52,"title":["Coagulation assessment with the new generation of oral anticoagulants"],"prefix":"10.1136","volume":"33","author":[{"suffix":"Jr","given":"Charles V","family":"Pollack","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2015,5,18]]},"reference":[{"key":"2024052701194209000_33.6.423.1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2295"},{"key":"2024052701194209000_33.6.423.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022913"},{"key":"2024052701194209000_33.6.423.3","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2291"},{"key":"2024052701194209000_33.6.423.4","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2292"},{"key":"2024052701194209000_33.6.423.5","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.13.1414"},{"key":"2024052701194209000_33.6.423.6","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2304"},{"key":"2024052701194209000_33.6.423.7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.177292"},{"key":"2024052701194209000_33.6.423.8","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-120-11-199406010-00001"},{"key":"2024052701194209000_33.6.423.9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.750000"},{"key":"2024052701194209000_33.6.423.10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.329.7456.15"},{"key":"2024052701194209000_33.6.423.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1103053"},{"key":"2024052701194209000_33.6.423.12","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1P670"},{"key":"2024052701194209000_33.6.423.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2011.01.018"},{"key":"2024052701194209000_33.6.423.14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.112.967299"},{"key":"2024052701194209000_33.6.423.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"2024052701194209000_33.6.423.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1007378"},{"key":"2024052701194209000_33.6.423.17","unstructured":"Boehringer Ingelheim Pharmaceuticals I. Pradaxa prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc., 2015:1\u201316."},{"key":"2024052701194209000_33.6.423.18","unstructured":"Janssen Pharmaceuticals I . Xarelto prescribing information. Titusville, NJ: Janssen Pharmaceuticals, Inc., 2014:1\u201313."},{"key":"2024052701194209000_33.6.423.19","unstructured":"Bristol-Meyers Squibb I . Eliquis prescribing information. Bristol-Meyers Squibb Company, 2014:1\u201330."},{"key":"2024052701194209000_33.6.423.20","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-11-1140"},{"key":"2024052701194209000_33.6.423.21","unstructured":"Daiichi Sankyo I . Savaysa prescribing information. Parsippany, NJ, USA: Daiichi Sankyo, Inc., 2015:32."},{"key":"2024052701194209000_33.6.423.22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.02899.x"},{"key":"2024052701194209000_33.6.423.23","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc. Highlights of prescribing information. Pradaxa (dabigatran etexilate mesylate) capsules for oral use. Ridgefield, CT, USA: Boehringer Ingelheim Pharmaceuticals, Inc., December 2012. 2014. (updated last updated April 2014 accessed 21 April 2014). http:\/\/bidocs.boehringer-ingelheim.com\/BIWebAccess\/ViewServlet.ser?docBase=renetnt&folderPath=\/Prescribing%20Information\/PIs\/Pradaxa\/Pradaxa.pdf"},{"key":"2024052701194209000_33.6.423.24","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-11-0758"},{"key":"2024052701194209000_33.6.423.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.10.017"},{"key":"2024052701194209000_33.6.423.26","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-06-0342"},{"key":"2024052701194209000_33.6.423.27","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Q105"},{"key":"2024052701194209000_33.6.423.28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.04098.x"},{"key":"2024052701194209000_33.6.423.29","unstructured":"Janssen Pharmaceuticals Inc. Highlights of prescribing information. Xarelto\u00ae (rivaroxaban) tablets for oral use. Janssen Pharmaceuticals, 2011. http:\/\/www.xareltohcp.com\/sites\/default\/files\/shared\/xarelto_0.pdf#zoom=100 (accessed 21 Apr 2014)."},{"key":"2024052701194209000_33.6.423.30","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-03-0176"},{"key":"2024052701194209000_33.6.423.31","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-005-0043-5"},{"key":"2024052701194209000_33.6.423.32","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000063575.17904.4E"},{"key":"2024052701194209000_33.6.423.33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2004.00775.x"},{"key":"2024052701194209000_33.6.423.34","unstructured":"Marlar RA , Cook J , Johnston M , et al . One-stage prothrombin time (PT) test and activated partial thromboplastin time (APTT) test; approved guideline. 2nd edn. Wayne, PA: Clinical and Laboratory Standards Institute, 2008. http:\/\/shopping.netsuite.com\/c.1253739\/site\/Sample_pdf\/H47-A2.pdf"},{"key":"2024052701194209000_33.6.423.35","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21470"},{"key":"2024052701194209000_33.6.423.36","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.10.1095"},{"key":"2024052701194209000_33.6.423.37","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.9.657"},{"key":"2024052701194209000_33.6.423.38","first-page":"A4383","article-title":"Excessive anticoagulation with warfarin or phenprocoumon may have multiple causes","volume":"59","author":"Meegaard","year":"2012","journal-title":"Dan Med J"},{"key":"2024052701194209000_33.6.423.39","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00988.x"},{"key":"2024052701194209000_33.6.423.40","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/109.5.595"},{"key":"2024052701194209000_33.6.423.41","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.023143"},{"key":"2024052701194209000_33.6.423.42","unstructured":"Bristol-Myers Squibb Company and Pfizer Inc. Highlights of prescribing information. Eliquis (apixaban) tablets for oral use. 2012. http:\/\/packageinserts.bms.com\/pi\/pi_eliquis.pdf (accessed 21 Apr 2014)."},{"key":"2024052701194209000_33.6.423.43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04369.x"},{"key":"2024052701194209000_33.6.423.44","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-05-0328"},{"key":"2024052701194209000_33.6.423.45","doi-asserted-by":"publisher","DOI":"10.1160\/TH11-11-0804"},{"key":"2024052701194209000_33.6.423.46","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0b013e32834f1b0c"},{"key":"2024052701194209000_33.6.423.47","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPAU7OQM0SRPZQ"},{"key":"2024052701194209000_33.6.423.48","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-012-0803-x"},{"key":"2024052701194209000_33.6.423.49","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-03-0204"},{"key":"2024052701194209000_33.6.423.50","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04309.x"},{"key":"2024052701194209000_33.6.423.51","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12166"},{"key":"2024052701194209000_33.6.423.52","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12165"},{"key":"2024052701194209000_33.6.423.53","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-011-0591-8"},{"key":"2024052701194209000_33.6.423.54","doi-asserted-by":"publisher","DOI":"10.1160\/TH11-09-0634"},{"key":"2024052701194209000_33.6.423.55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04498.x"},{"key":"2024052701194209000_33.6.423.56","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc. Advisory committee briefing document: dabigatran etexilate. 2010. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterialsDrugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/UCM226009.pdf (accessed 21 Apr 2014)."},{"key":"2024052701194209000_33.6.423.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2007.06.034"},{"key":"2024052701194209000_33.6.423.58","doi-asserted-by":"publisher","DOI":"10.2165\/11318170-000000000-00000"},{"key":"2024052701194209000_33.6.423.59","unstructured":"Richter KC . TAS Ecarin clotting time test. Administration FaD, 2000."},{"key":"2024052701194209000_33.6.423.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.09.058"},{"key":"2024052701194209000_33.6.423.61","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21469"},{"key":"2024052701194209000_33.6.423.62","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0b013e3181ec611b"},{"issue":"(21 Suppl)","key":"2024052701194209000_33.6.423.63","first-page":"A9928","article-title":"Reversal of anticoagulant activity of dabigatran and dabigatran-induced bleeding in rats by a specific antidote (antibody fragment) [abstract]","volume":"126","author":"van Ryn","year":"2012","journal-title":"Circulation"},{"issue":"(Suppl 1)","key":"2024052701194209000_33.6.423.64","first-page":"496","article-title":"Recombinant factor Xa inhibitor antidote (PRT064445) mediates reversal of anticoagulation through reduction of free drug concentration: a common mechanism for direct factor Xa inhibitors","volume":"33","author":"Hutchaleelaha","year":"2012","journal-title":"Eur Heart J"},{"key":"2024052701194209000_33.6.423.65","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12599"},{"key":"2024052701194209000_33.6.423.66","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-08-0573"},{"key":"2024052701194209000_33.6.423.67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"2024052701194209000_33.6.423.68","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht135"},{"key":"2024052701194209000_33.6.423.69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310907"},{"key":"2024052701194209000_33.6.423.70","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-468207"},{"key":"2024052701194209000_33.6.423.71","unstructured":"Boehringer Ingelheim GmbH. Boehringer Ingelheim's Investigational Antidote for Pradaxa\u00ae (dabigatran etexilate mesylate) Receives FDA Breakthrough Therapy Designation. Ridgefield, CT: Boehringer Ingelheim GmbH, 2014. (updated 26 June 2014; cited 12 August 2014; Press release). http:\/\/us.boehringer-ingelheim.com\/news_events\/press_releases\/press_release_archive\/2014\/06-26-14-boehringer-ingelheim-investigational-antidote-pradaxa-dabigatran-etexilate-mesylate-fda-breakthrough-therapy-designation.html"},{"key":"2024052701194209000_33.6.423.72","doi-asserted-by":"crossref","unstructured":"Vandana M , Michael K , Genmin L , et al , eds. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for Fxa inhibitors. Presented at: 55th American Society of Hematology Annual Meeting and Exposition; Abstract 3636 7\u201310 December 2013; New Orleans: Louisiana.","DOI":"10.1182\/blood.V122.21.3636.3636"},{"key":"2024052701194209000_33.6.423.73","unstructured":"Portola Pharmaceuticals I. Portola Pharmaceuticals Receives Breakthrough Therapy Designation From FDA for Andexanet Alfa (PRT4445*), Investigational Factor Xa Inhibitor Antidote. [Webpage] 2013. http:\/\/investors.portola.com\/phoenix.zhtml?c=198136&p=irol-newsArticle&ID=1879666 (cited 22 Sept 2014)."},{"key":"2024052701194209000_33.6.423.74","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03753.x"},{"key":"2024052701194209000_33.6.423.75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.05.007"},{"key":"2024052701194209000_33.6.423.76","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs274"},{"key":"2024052701194209000_33.6.423.77","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23202"},{"key":"2024052701194209000_33.6.423.78","unstructured":"Glund S , Stangier J , Schmohl M , et al . A specific antidote for dabigatran: Immediate, complete and sustained reversal of dabigatran induced anticoagulation in healthy male volunteers. Presented at: American Heart Association Scientific Sessions 2013; November 17\u201319, 2013; Dallas, Texas2013."},{"key":"2024052701194209000_33.6.423.79","unstructured":"Portola Pharmaceuticals I . Andexanet alfa: FXa Inhibitor Antidote. [Webpage]. 2014. (updated 2014; cited 14 Aug 2014). http:\/\/www.portola.com\/clinical-development\/andexanet-alfa-prt4445-fxa-inhibitor-antidote\/"},{"key":"2024052701194209000_33.6.423.80","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPQ2NJD3PXFTUG"}],"container-title":["Emergency Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/emermed-2015-204891","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T04:19:55Z","timestamp":1716783595000},"score":1,"resource":{"primary":{"URL":"https:\/\/emj.bmj.com\/lookup\/doi\/10.1136\/emermed-2015-204891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,18]]},"references-count":80,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,5,19]]},"published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1136\/emermed-2015-204891"],"URL":"https:\/\/doi.org\/10.1136\/emermed-2015-204891","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725514035.793533049","asserted-by":"object"}]},"ISSN":["1472-0205","1472-0213"],"issn-type":[{"value":"1472-0205","type":"print"},{"value":"1472-0213","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,18]]}}}